Board Meeting Details

The Board of Directors meeting was held on Wednesday, 28th October 2026, commencing at 2:45 p.m. and concluding at 4:30 p.m. The meeting was previously intimated to the exchanges via letter dated 22nd October 2026.

Financial Results Approval

The Board considered and approved the Unaudited Financial Results for the quarter and nine months ended 30th September 2026.

Quarterly Financial Performance (₹ in Million)

  • Revenue from Operations: ₹2,631 (Q3 FY26) vs ₹2,339 (Q3 FY25) - 12% increase
  • Other Income: ₹44 (Q3 FY26) vs ₹30 (Q3 FY25)
  • Total Income: ₹2,675 (Q3 FY26) vs ₹2,369 (Q3 FY25)
  • Expenses Breakdown:
  • Cost of Materials Consumed: ₹407
  • Purchases of stock in trade: ₹116
  • Changes in Inventories: ₹121
  • Employee benefits expense: ₹307
  • Finance costs: ₹3
  • Depreciation and amortisation: ₹31
  • Other expenses: ₹663
  • Total Expenses: ₹1,648
  • Profit before exceptional item and tax: ₹1,027
  • Exceptional item: None (₹0)
  • Profit before tax: ₹1,027 (22% increase from ₹841 in Q3 FY25)
  • Tax expense: ₹266
  • Profit for the period: ₹766
  • Other comprehensive income: ₹(8) net
  • Total comprehensive income: ₹758
  • Basic and diluted EPS: ₹33.26 (22% increase from ₹27.31 in Q3 FY25)

Nine-Month Financial Performance (₹ in Million)

  • Revenue from Operations: ₹7,280 (9M FY26) vs ₹6,274 (9M FY25) - 16% increase
  • Other Income: ₹163 (9M FY26) vs ₹138 (9M FY25)
  • Total Income: ₹7,443 (9M FY26) vs ₹6,412 (9M FY25)
  • Expenses Breakdown:
  • Cost of Materials Consumed: ₹1,284
  • Purchases of stock in trade: ₹457
  • Changes in Inventories: ₹28
  • Employee benefits expense: ₹951
  • Finance costs: ₹12
  • Depreciation and amortisation: ₹96
  • Other expenses: ₹1,762
  • Total Expenses: ₹4,590
  • Profit before exceptional item and tax: ₹2,853
  • Exceptional item: None (₹0) vs ₹66 reversal in 9M FY25
  • Profit before tax: ₹2,853 (24% increase from ₹2,298 in 9M FY25)
  • Tax expense: ₹741
  • Profit for the period: ₹2,132
  • Other comprehensive income: ₹(8) net
  • Total comprehensive income: ₹2,124
  • Basic and diluted EPS: ₹92.57 (23% increase from ₹75.38 in 9M FY25)

Capital Structure

  • Paid-up equity share capital: ₹230 million (Face Value of ₹10 per share) - unchanged across all periods
  • Other equity: Not separately disclosed for interim periods

Sales Breakdown

Revenue from operations includes sales of products and service income. Sales of products specifically:

  • Q3 FY26: ₹2,438 million
  • Q2 FY26: ₹2,132 million
  • Q3 FY25: ₹2,132 million
  • 9M FY26: ₹6,634 million
  • 9M FY25: ₹5,715 million
  • FY25: ₹8,045 million

Operational Highlights

  • Domestic sales grew 19% year-on-year in Q3 FY26
  • Domestic sales grew 15% year-on-year for nine months FY26, aided by product relaunches
  • Export sales grew 19% year-on-year for nine months FY26
  • The company successfully relaunched Combiflam Suspension in Q2 FY25 and Allegra Suspension and Depura Kids in Q3 FY25 following a voluntary recall in 2024

Comparability Note

The results are not fully comparable with the nine months of the previous year due to the product recall and subsequent relaunches of Combiflam Suspension, Allegra Suspension and Depura Kids, which had an impact on the domestic business.

Exceptional Items

For nine months ended September 30, 2025 and year ended December 31, 2025, there was an exceptional item pertaining to the reversal of ₹66 million related to demerger provisions made in 2024. No exceptional items were recorded in the current period.

Segment Information

The Company has a single business segment namely 'Pharmaceutical Business'. Therefore, segment disclosures under Ind AS 108 are not applicable.

Subsidiaries and Associates

The Company does not have any subsidiary, associates or joint ventures as on September 30, 2026.

Review and Approval Process

The results were reviewed by the Audit Committee and approved by the Board of Directors. Price Waterhouse & Co Chartered Accountants LLP conducted a limited review and issued an unmodified conclusion, stating that nothing has come to their attention that causes them to believe that the Statement has not been prepared in all material respects in accordance with applicable standards.

Publication and Availability

Extract of the results will be published in newspapers in the format prescribed under Regulation 47 of the SEBI Listing Regulations. The results are also available on the Company's website at https://www.sanofi.com/en/india/consumer-healthcare/investors/financial-results.